The Latest

COUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP-106 in Generalized Myasthenia Gravis

Skip to primary navigation
Skip to main content
Skip to footer

COUR Pharmaceuticals

Our Company
Our Technology
- Pipeline
Our Clinical Trials
- CNP-106 Myasthenia Gravis
Publications & Media
- Press Releases
- Publications
Careers

Robert F. Carey

Lead Independent Director

Board Of Director at COUR Pharmaceuticals Robert F. Carey

Footer

Our Company
Our Technology
Our Partners
Press
Careers

©

2024

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use